阿巴洛肽对全髋关节置换术中股骨近端Gruen分区骨密度的影响:一项针对绝经后骨质疏松女性的研究
该研究为ACTIVE试验的事后分析,纳入500例绝经后骨质疏松女性,随机接受阿巴洛肽(250例)或安慰剂(250例)治疗,通过三维建模模拟全髋关节置换股骨柄并划分Gruen分区。结果显示,与安慰剂相比,阿巴洛肽组在6个月和18个月时多个分区的骨密度指标有更大提升,作者认为阿巴洛肽可能对拟行全髋关节置换的骨质疏松患者骨健康优化具有价值。
要点
- 阿巴洛肽组在6个月和18个月时所有分区的整体体积骨密度增幅均大于安慰剂组。
- 18个月时,阿巴洛肽组所有分区的皮质厚度、皮质体积骨密度和皮质表面骨密度增幅均大于安慰剂组。
- 作者认为阿巴洛肽可能对拟行全髋关节置换的骨质疏松患者术前或围手术期骨健康优化具有价值。
核心结论
- 阿巴洛肽可增加与股骨柄相互作用并支撑股骨柄的股骨近端区域的骨密度,提示其可能对拟行全髋关节置换的骨质疏松患者术前或围手术期骨健康优化具有价值。
研究设计与样本
- 本研究为ACTIVE试验(NCT01343004)的事后分析,从该三期试验中随机选取500例绝经后骨质疏松女性,在阿巴洛肽(250例)或安慰剂(250例)治疗0、6和18个月时获取髋部双能X线吸收测定(DXA)扫描。
- 髋部DXA扫描经3D-Shaper进行三维建模,随后虚拟切除股骨近端并模拟置入锥形平楔股骨柄,据此划定扫描区域内完全捕获(1区和7区)或大部分捕获(2区和6区)的Gruen分区。
- 测定每个分区的整体、皮质和骨小梁体积骨密度、皮质厚度及皮质表面骨密度(皮质体积骨密度与皮质厚度的乘积)。
主要发现
- 与安慰剂组相比,阿巴洛肽组在第6个月和第18个月时所有分区的整体体积骨密度增幅更大。
- 与安慰剂组相比,阿巴洛肽组在第6个月时1、6和7区的皮质表面骨密度增幅更大。
- 与安慰剂组相比,阿巴洛肽组在第18个月时所有分区的皮质厚度、皮质体积骨密度和皮质表面骨密度增幅更大。
- 与安慰剂组相比,阿巴洛肽组在第6个月和第18个月时1区和7区的骨小梁体积骨密度增幅更大。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Low hip bone mineral density (BMD) in patients who undergo total hip arthroplasty (THA) increases the risk of periprosthetic fractures, implant instability, and other complications. Recently, emphasis has been placed on bone health optimization: treating low BMD prior to a planned orthopaedic implant procedure in an effort to normalize BMD and reduce the potential risk of future complications. Abaloparatide is a U.S. Food and Drug Administration-approved osteoanabolic agent for men and postmenopausal women with osteoporosis and a candidate drug for bone health optimization that, in addition to benefits at the spine, increases hip BMD and reduces nonvertebral fracture risk. We hypothesized that abaloparatide would improve BMD in proximal femoral regions surrounding a virtual THA stem. METHODS: This post hoc analysis obtained dual x-ray absorptiometry (DXA) hip scans from 500 randomly selected postmenopausal women with osteoporosis from the Phase-3 Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE, NCT01343004) study after 0, 6, and 18 months of abaloparatide (250 patients) or placebo (250 patients). Hip DXA scans underwent 3-dimensional (3D) modeling via 3D-Shaper, followed by virtual resection of the proximal femur and simulated placement of a tapered, flat-wedge hip stem that guided delineation of the Gruen zones that were fully (zones 1 and 7) or largely (zones 2 and 6) captured in the scanning region. Integral, cortical, and trabecular volumetric BMD, cortical thickness, and cortical surface BMD (the product of cortical volumetric BMD and cortical thickness) were determined for each zone. RESULTS: Compared with placebo, the abaloparatide group showed greater increases in integral volumetric BMD in all zones at months 6 and 18; cortical surface BMD in zones 1, 6, and 7 at month 6; cortical thickness, cortical volumetric BMD, and cortical surface BMD in all zones at month 18; and trabecular volumetric BMD in zones 1 and 7 at months 6 and 18. CONCLUSIONS: Abaloparatide increases BMD in proximal femoral regions that interact with and support femoral stems, suggesting that abaloparatide may have value for preoperative or potentially perioperative bone health optimization in patients with osteoporosis undergoing THA. LEVEL OF EVIDENCE: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
引用
- Sheth NP, Smith JR, Winzenrieth R, et al. Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones: A Study of Postmenopausal Women with Osteoporosis. J Bone Joint Surg Am. 2024. PMID: 38691582. doi:10.2106/JBJS.23.01334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。